Current treatment of peripheral T-cell lymphoma Review
| Authors: | Stuver, R.; Epstein-Peterson, Z. D.; Johnson, W. T.; Khan, N.; Lewis, N.; Moskowitz, A. J.; Sauter, C. S.; Horwitz, S. M. |
| Review Title: | Current treatment of peripheral T-cell lymphoma |
| Abstract: | The peripheral T-cell lymphomas (PTCLs) are a notoriously diverse family of non-Hodgkin lymphomas with generally aggressive biology. Clinical management is challenging given a largely inadequate literature base comprised of few randomized trials and heterogeneous observational reports. Herein, we provide an account of our practice in the treatment of the 3 most common nodal PTCLs: PTCL, not otherwise specifi ed, angioimmunoblastic T-cell lymphoma, and anaplastic large cell lymphoma (ALCL). In the up-front setting, we employ anthracycline-based induction, with the incorporation of brentuximab vedotin for all those with ALCL and consideration in those with other CD30-expressing PTCLs based on improved progression-free and overall survival in the absence of additional toxicity in the ECHELON-2 trial. We strongly consider high-dose therapy with autologous stem cell rescue in fi rst complete remission. In the relapsed or refractory (R/R) setting, we often look to clinical trials or choose from 4 FDA-approved single agents--belinostat, brentuximab vedotin, romidepsin, and pralatrexate--based on tumor phenotype and side-effect profi les. Our goal in the R/R setting is achievement of complete remission followed by allogeneic transplant with curative intent in appropriate candidates or long-term disease control in others. Numerous investigational agents are advancing through trials and have potential to alter standards of care in the near future. |
| Keywords: | drug approval; united states food and drug administration; progression-free survival; antineoplastic agents -- therapeutic use; chemotherapy, cancer; neoplasm recurrence, local -- drug therapy; antibodies, monoclonal -- therapeutic use; allografts; disease remission; lymphoma, t-cell -- drug therapy; lymphoma, t-cell -- diagnosis; anthracyclines -- therapeutic use |
| Journal Title: | Oncology (Norwalk) |
| Volume: | 36 |
| Issue: | 5 |
| ISSN: | 0890-9091 |
| Publisher: | C M P Medica LLC * The Oncology Group |
| Date Published: | 2022-05-01 |
| Start Page: | 293 |
| End Page: | 305 |
| Language: | English |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| PUBMED: | 35576176 |
| DOI: | 10.46883/2022.25920960 |
| DOI/URL: | |
| Notes: | Source: Cinahl |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work